Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 578 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Clinical Benefit and Genomic Features Associations Observed with Pembrolizumab Plus Axitinib... August 21, 2025 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 Artificial Intelligence May Aid in the Discrimination of Radiation Pneumonitis from... March 24, 2021 Girls Become Best Friends In Hospital, Reunite Years Later For “Survivors”... March 22, 2019 Load more HOT NEWS Research with integrity – why colour blindness is a research integrity... Darolutamide Extends Survival for Some People with Metastatic Prostate Cancer New breast and lung cancer treatments approved in Scotland Using Technology to Find Cancers Early and Exercise Improves Sexual Health...
